Royce & Associates LP Has $35.84 Million Stock Holdings in Azenta, Inc. (NASDAQ:AZTA)

Royce & Associates LP lifted its holdings in Azenta, Inc. (NASDAQ:AZTA) by 7.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 739,977 shares of the company’s stock after buying an additional 53,584 shares during the period. Royce & Associates LP owned about 1.51% of Azenta worth $35,844,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Hantz Financial Services Inc. acquired a new stake in shares of Azenta in the second quarter worth $30,000. Farther Finance Advisors LLC boosted its position in shares of Azenta by 20.0% in the third quarter. Farther Finance Advisors LLC now owns 1,537 shares of the company’s stock worth $74,000 after buying an additional 256 shares during the period. Benjamin F. Edwards & Company Inc. boosted its position in shares of Azenta by 150.9% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,588 shares of the company’s stock worth $84,000 after buying an additional 955 shares during the period. Lazard Asset Management LLC acquired a new stake in shares of Azenta in the first quarter worth $130,000. Finally, Acadian Asset Management LLC boosted its position in shares of Azenta by 24.7% in the first quarter. Acadian Asset Management LLC now owns 2,381 shares of the company’s stock worth $143,000 after buying an additional 471 shares during the period. Institutional investors and hedge funds own 99.08% of the company’s stock.

Azenta Price Performance

AZTA opened at $42.63 on Friday. Azenta, Inc. has a 1 year low of $40.24 and a 1 year high of $69.16. The stock has a fifty day moving average price of $45.68 and a 200 day moving average price of $50.54.

Azenta (NASDAQ:AZTA) last posted its earnings results on Tuesday, November 12th. The company reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.10 by $0.08. Azenta had a positive return on equity of 1.03% and a negative net margin of 25.01%. The company had revenue of $170.00 million for the quarter, compared to analyst estimates of $169.66 million. During the same period last year, the company earned $0.13 earnings per share. The business’s revenue was down 1.2% compared to the same quarter last year. Research analysts expect that Azenta, Inc. will post 0.42 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on AZTA shares. Needham & Company LLC reduced their price objective on Azenta from $69.00 to $55.00 and set a “buy” rating for the company in a research report on Wednesday. Evercore ISI reduced their price objective on Azenta from $53.00 to $50.00 and set an “in-line” rating for the company in a research report on Tuesday, October 1st. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $63.60.

Insider Buying and Selling at Azenta

In other Azenta news, CFO Herman Cueto sold 1,595 shares of the firm’s stock in a transaction dated Thursday, October 17th. The stock was sold at an average price of $43.68, for a total transaction of $69,669.60. Following the transaction, the chief financial officer now directly owns 24,604 shares in the company, valued at $1,074,702.72. This trade represents a 6.09 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.77% of the company’s stock.

Azenta Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.